{
    "clinical_study": {
        "@rank": "65378", 
        "arm_group": [
            {
                "arm_group_label": "AADs", 
                "arm_group_type": "Active Comparator", 
                "description": "AAD therapy based on hospital clinical practice according to ESC Guidelines 2012"
            }, 
            {
                "arm_group_label": "Cryoablation procedure", 
                "arm_group_type": "Experimental", 
                "description": "electrical pulmonary veins isolation performed with cryoballoon ablation system"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the effectiveness of Pulmonary Vein Isolation (PVI)\n      performed with the Arctic Front\u2122 Advance Cardiac CryoAblation Catheter System as first-line\n      therapy in comparison with antiarrhythmic drugs (AAD) in patients with paroxysmal atrial\n      fibrillation (AF)."
        }, 
        "brief_title": "Catheter Cryoablation Versus Antiarrhythmic Drug as First-Line Therapy of Paroxysmal Atrial Fibrillation", 
        "condition": "Symptomatic Paroxysmal Atrial Fibrillation Without Clinically Significant Heart Diseases", 
        "condition_browse": {
            "mesh_term": [
                "Atrial Fibrillation", 
                "Heart Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject has been diagnosed with symptomatic paroxysmal atrial fibrillation as defined\n             above with a history of at least three months of known AF and at least two\n             symptomatic episodes in the last three months prior to inclusion.\n\n          -  At least one episode of AF must be documented during the prior year by any kind of\n             ECG recording.\n\n          -  Subject has structural normal heart with an LVEF \u2265 50%, thickness of the\n             inter-ventricular septum <11 mm and left atrium diameters (short axis) < 46 mm\n             obtained by transthoracic echocardiography.\n\n          -  Subject has normal ECG parameters (QRS width in the 12 channel surface ECG \u2264110 ms,\n             QTc - interval  < 440 ms, PQ - interval \u2264 210 ms; all parameters should be  measured\n             at sinus rhythm).\n\n          -  Subject is at least 18 and \u226475 years of age old.\n\n          -  Subject is able and willing to give informed consent\n\n        Exclusion Criteria:\n\n          -  Subject developed persistent AF at least once in history (electrical or\n             pharmacological cardioversion after 48h or episode duration >7 days).\n\n          -  Subject has documented typical atrial flutter.\n\n          -  Subject has any history of successful or unsuccessful treatment of AF with class I or\n             III antiarrhythmic or sotalol with a sufficient dose and time of application\n             according to current guidelines.\n\n          -  Subject had any previous left atrial ablation.\n\n          -  Subject had any previous cardiac surgery, e.g. prosthetic valves.\n\n          -  Subject has permanent pacemaker or defibrillator implant.\n\n          -  Subject has 2\u00b0 type II, 3\u00b0 degree AV-block or left/right bundle branch block pattern\n\n          -  Subject has unstable angina pectoris.\n\n          -  Subject has history of previous myocardial infarction or percutaneous intervention\n             during the last three months.\n\n          -  Subject has symptomatic carotid stenosis.\n\n          -  Subject has chronic obstructive pulmonary disease with detected pulmonary\n             hypertension or any other evidence of significant lung disease.\n\n          -  Subject has any contraindication for oral anticoagulation.\n\n          -  Subject has any history of previous transient ischemic attack or stroke.\n\n          -  Subject has known intra-cardiac thrombus formation.\n\n          -  Subject has any significant congenital heart defect corrected or not (except for\n             patent foramen ovale that is allowed).\n\n          -  Subject has evidence of congestive heart failure (NYHA class II, III or IV) in sinus\n             rhythm.\n\n          -  Subject has hypertrophic cardiomyopathy.\n\n          -  Subject has abnormal long or short QT interval, signs of Brugada syndrome, known\n             inheriting ion channel disease on the family, arrhythmogenic right ventricular\n             dysplasia.\n\n          -  Subject has sarcoidosis.\n\n          -  Subject has pulmonary vein stent.\n\n          -  Subject has myxoma. Exclusion criteria based on laboratory abnormalities\n\n          -  Subject has thrombocytosis (platelet count > 600,000 / \u03bcl) or thrombocytopenia\n             (platelet count <100,000 / \u03bcl).\n\n          -  Subject has any untreated or uncontrolled hyperthyroidism or hypothyroidism.\n\n          -  Subject has renal dysfunction with glomerular filtration rate  < 80 ml / min.\n\n          -  Subject has known cryoglobulinaemia. General exclusion criteria\n\n          -  Subject has a reversible causes for AF like hyperthyroidism and alcoholism.\n\n          -  Subject is a pregnant woman or woman of childbearing potential not on adequate birth\n             control: only woman with a highly effective method of contraception [oral\n             contraception or intra-uterine device] (who must have a negative pregnancy test\n             within 1 week of randomization) or sterile woman can be enrolled.\n\n          -  Subject is a breastfeeding woman.\n\n          -  Subject has an active systemic infection.\n\n          -  Subject is employed by Medtronic or by the department of any of the investigators or\n             is a close relative of any of the investigators.\n\n          -  Subject is unwilling or unable to comply fully with study procedures and follow-up\n             due to any disease condition, which can raise doubt about compliance and influencing\n             the study outcome especially any kind of cancer, severe bleeding in history or a\n             suspected pro-coagulant state.\n\n          -  Legal incapacity or evidence that a subject cannot understand the purpose and risks\n             of the study or inability to comply fully with study procedures and follow up.\n\n          -  Subject has a life expectancy of \u2264 1 year.\n\n          -  Subject is participating in any other clinical study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "218", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 1, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01803438", 
            "org_study_id": "Cryo-FIRST"
        }, 
        "intervention": [
            {
                "arm_group_label": "Cryoablation procedure", 
                "intervention_name": "cryoballoon ablation system", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "AADs", 
                "description": "AAD therapy based on hospital clinical practice according to ESC Guidelines 2012", 
                "intervention_name": "Antiarrhythmic Drugs", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Anti-Arrhythmia Agents"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "paroxysmal Atrial Fibrillation", 
            "Cryoablation", 
            "Pulmonary Vein Isolation"
        ], 
        "lastchanged_date": "June 4, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Brussel", 
                        "country": "Belgium"
                    }, 
                    "name": "Heart Rhythm Management Centre, UZ Brussels - VUB Brussel"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Amiens", 
                        "country": "France"
                    }, 
                    "name": "CHU Amiens"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Olivier Cesari, MD"
                }, 
                "contact_backup": {
                    "last_name": "Christophe Loose, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Tours", 
                        "country": "France", 
                        "zip": "37000"
                    }, 
                    "name": "Clinique Saint Gatien"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bad Nauheim", 
                        "country": "Germany"
                    }, 
                    "name": "Kerckhoff - Klinik"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Belgium", 
                "France", 
                "Germany"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "Catheter Cryoablation Versus Antiarrhythmic Drug as First-Line Therapy of Paroxysmal Atrial Fibrillation.", 
        "overall_contact": {
            "email": "laura.manotta@/medtronic.com", 
            "last_name": "Laura Manotta, MS", 
            "phone": "+39 02 241371"
        }, 
        "overall_official": [
            {
                "affiliation": "Kerckhoff - Klinik, Bad Nauheim, Germany", 
                "last_name": "Malte Kuniss, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Heart Rhythm Management Centre, UZ Brussels - VUB Brussel, Belgium", 
                "last_name": "GianBattista Chierchia, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "France: ANSM", 
                "Germany: Federal Institute for Drugs and Medical Devices"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "June 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary endpoint is freedom from any atrial arrhythmia recurrence at 12 months (at least one episode of AF, atrial flutter or atrial tachycardia with a duration > 30 seconds documented by 7 day Holter ECG or any other printed ECG recording following a blanking period or a dosing optimizing period of 3 months).", 
            "measure": "Freedom from any atrial arrhythmia recurrence", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01803438"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The quality of life of the two arms measured by means of SF-36 Health Survey and Atrial Fibrillation Effect on QualiTy-of-Life (AFEQT) questionnaires will be compared at 12 months follow-up.", 
                "measure": "quality of life", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Hospital or emergency services accesses due to symptoms caused by documented atrial arrhythmias will be compared in the two arms at 12 months follow-up.", 
                "measure": "Hospital or emergency services accesses", 
                "safety_issue": "No", 
                "time_frame": "12 Months"
            }, 
            {
                "description": "Freedom from occurrence of AF (after 3 months blanking period) will be compared between the two arms at 12 months follow-up.", 
                "measure": "Freedom from occurrence of AF", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Freedom from occurrence of documented left atrial tachycardia and typical - or atypical left atrial flutter (after 3 months blanking period or AAD optimization period) will be compared between the two arms at 12 months follow-up.", 
                "measure": "Freedom from occurrence of documented left atrial tachycardia and left atrial flutter", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Symptomatic palpitations burden will be evaluated by mean of Patient's diary information and compared between the two arms at 12 months follow-up.", 
                "measure": "Symptomatic palpitations burden", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Severe adverse events incidence will be compared between the two arms during the whole course of the study.", 
                "measure": "Severe adverse events incidence", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Freedom from persistent AF (AF episode lasting longer than 7 days or interrupted by pharmacological or electrical cardioversion after 48h from the onset of the episode) will be compared between the two arms at 12 months follow-up.", 
                "measure": "Freedom from persistent AF", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Echocardiographic left atrial parameters will be compared between the two arms at 6 and 12 months follow ups.", 
                "measure": "Echocardiographic left atrial re-modelling", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Frequency, type and associated cost of health care utilization and utility will be compared between the two arms at 12 months follow-up.", 
                "measure": "health care utilization", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }
        ], 
        "source": "Medtronic Bakken Research Center", 
        "sponsors": {
            "collaborator": {
                "agency": "Medtronic Atrial Fibrillation Solutions", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Medtronic Bakken Research Center", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}